TICKERNERD
Menu
RDNTRDNTHealthcare · Diagnostics & Research

RDNT Stock Forecast: RadNet, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$69
−3.29% on the day

The 8 Wall Street analysts covering RadNet, Inc. hold a median 12-month price target of $96 — +38.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.6B
Ticker Nerd rank
36 / 100
Median analyst target
$96
Analysts covering
8
Revenue$622.7M+25.0% y/y
Operating income$42.6M
Net income$20.3M
Free cash flow$37.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
−8.4%
YTD
−3.1%
1Y
−6.3%
From 52W high
−18.1%
From 52W low
+33.3%
$52
$84
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RDNT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores RadNet, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
71
Momentum
68
Volatility
61
Revisions
59
Accruals
56
Value
33
Quality
32
Size
21
Issuance
17

Growth (71): Sales and profits are climbing, and climbing faster than before.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RDNT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RDNT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100$110Jan 26Apr 26Jul 26Oct 26RDNTHigh $105Median $96Low $79

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $79Median $96High $105

The green dot is the last close — the median target sits +38.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
28 Aug 2026BarclaysMaintainsOverweight$65 → $79
11 Aug 2026Truist SecuritiesMaintainsBuy$90 → $94
11 Aug 2026Truist SecuritiesMaintainsBuy—
20 May 2026BarclaysMaintainsOverweight$70 → $65
20 May 2026BarclaysMaintainsOverweight—
21 Apr 2026BarclaysMaintainsOverweight—
9 Jan 2026KeybancInitiatesOverweight—
1 Dec 2025B. Riley SecuritiesMaintainsBuy—
13 Nov 2025BarclaysMaintainsOverweight—
12 Nov 2025Truist SecuritiesMaintainsBuy—
3 Sept 2025BarclaysMaintainsOverweight—
3 Sept 2025Truist SecuritiesMaintainsBuy—
13 Aug 2025Raymond JamesReiteratesStrong Buy—
13 June 2025B. Riley SecuritiesInitiatesBuy—
11 Apr 2025Truist SecuritiesMaintainsBuy—
24 Mar 2025BarclaysMaintainsOverweight—
5 Mar 2025Raymond JamesUpgradeStrong Buy—
22 Jan 2025BarclaysMaintainsOverweight—
22 Jan 2025Truist SecuritiesReiteratesBuy—
15 Jan 2025JefferiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RDNT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RDNT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, RadNet, Inc. returned −6.3% against +17.5% for the S&P 500, dividends included.

RDNT vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26RDNTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RDNT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
4
Analysts cutting
3
Fundamentals

RadNet, Inc. (RDNT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1425.8×

Cheaper than 1% of US stocks

Price / sales
2.5×

Cheaper than 46% of US stocks

Price / book
5.1×

Cheaper than 19% of US stocks

EV / EBITDA
26.7×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
25.0%

Higher than 74% of US stocks

Earnings growth (YoY)
−47.9%

Higher than 11% of US stocks

Gross margin
14.1%

Higher than 13% of US stocks

Operating margin
7.9%

Higher than 60% of US stocks

Net margin
−0.9%

Higher than 29% of US stocks

Returns & dividend
Return on equity
1.5%

Higher than 46% of US stocks

Return on assets
1.7%

Higher than 56% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

RadNet, Inc. (RDNT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • RadNet, Inc. has a market value of $5.6B and an enterprise value of $7.4B.

  • Revenue in the twelve months to 30 June 2026: $2.3B. The latest quarter grew 25.0% year on year.

  • Net income over the same four quarters: $19.3M, a 0.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $72.4M.

  • Shares outstanding: 78.6M.

  • Trailing P/E: 1425.8×; forward P/E: 80.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • RadNet, Inc. employs 11,000 people — $206K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

RDNT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
RDNTRadNet, Inc.$5.6B
36
SHCSotera Health Co.$5.0B
97
BLLNBillionToOne, Inc.$4.6B
15
GRALGRAIL, Inc.$6.2B
38
ADPTAdaptive Biotechnologies Corp.$4.1B
73
VCYTVeracyte, Inc.$3.5B
96
CDNACareDx, Inc.$3.3B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own RadNet, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RDNT news & analysis

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

GlobeNewsWire · 8 Oct 2026positive

DeepHealth, a wholly owned RadNet subsidiary, announced findings published in European Radiology suggesting its Prostate MR Solution AI applications could help clinicians determine which men may need a biopsy, especially when MRI results are uncertain.

Why it matters — The findings relate to a DeepHealth product within RadNet's health informatics business and its potential role in prostate biopsy decision-making.

RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals

GlobeNewsWire · 1 Oct 2026positive

RadNet announced a collaboration with WIN-NextGen™ to launch a program introducing students and young adults to careers in radiology through mentorship, digital experiences, and hands-on learning. The initiative was announced in Owings Mills, Maryland.

Why it matters — This collaboration could help build a future pipeline of radiology professionals, supporting the industry talent base that RadNet relies on.

RadNet, Inc. (RDNT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

RadNet, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and the transcript of its presentation was published by Seeking Alpha. The news item reports on RadNet's participation in the investor conference.

Why it matters — A RadNet watcher would care because the company's presentation at a major healthcare investment conference offers insight into how it communicates its business to the investment community.

RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026

GlobeNewsWire · 9 Sept 2026neutral

RadNet, Inc. announced that Executive Vice President and Chief Financial Officer Mark Stolper will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026, at 7:45 a.m. Eastern Time.

Why it matters — RadNet watchers would care because the company's CFO will be presenting at a major investment conference, offering an opportunity to hear updates on the company directly.

RadNet to Host Free Prostate Cancer Webinar on September 19, 2026

GlobeNewsWire · 9 Sept 2026positive

RadNet, Inc. announced it will host a free webinar for patients and the general public on Saturday, September 19, 2026, in support of Prostate Cancer Awareness Month. The event was announced via a press release on September 9, 2026.

Why it matters — The free educational webinar highlights RadNet's patient engagement and community outreach during Prostate Cancer Awareness Month, reinforcing its role as a leader in diagnostic imaging services.

FAQ

Frequently asked questions about RDNT stock

What is the RDNT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering RadNet, Inc. have a median 12-month price target of $96, with estimates ranging from $79 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RDNT stock a buy right now?

Of the 8 analysts covering RadNet, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks RadNet, Inc. 36 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RDNT?

As at 14 Oct 2026, RadNet, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (71 of 100).

Will RDNT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +38.1% from the last close, and Ticker Nerd's factor model ranks RadNet, Inc. 36 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RDNT stock forecast for 2030?

No analyst covering RadNet, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RDNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $105 over the next 12 months.

How has RDNT stock performed over the past year?

RadNet, Inc. returned -6.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does RadNet, Inc. do?

RadNet Inc. is a healthcare services company that provides outpatient diagnostic imaging services across the United States.

What is the latest news on RDNT?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies". DeepHealth, a wholly owned RadNet subsidiary, announced findings published in European Radiology suggesting its Prostate MR Solution AI applications could help clinicians determine which men may need a biopsy, especially when MRI results are uncertain.

Company

About RadNet, Inc.

RadNet Inc. is a healthcare services company that provides outpatient diagnostic imaging services across the United States. The company operates a large network of fixed-site imaging centers offering services such as MRI, CT, PET, mammography, ultrasound, X-ray, fluoroscopy, and nuclear medicine to support physicians in the diagnosis and treatment of disease. RadNet also develops digital health and radiology technology solutions through its DeepHealth platform, including software and AI-enabled tools designed to improve image interpretation, workflow efficiency, and clinical decision support. Its business is organized around imaging centers and digital health, giving it a role at the intersection of medical diagnostics and healthcare technology. RadNet serves patients, referring physicians, and healthcare providers, with a focus on accessible, high-volume outpatient imaging and radiology informatics.

CEO Dr. Howard G. Berger M.D. · 11,000 employees · United States · https://www.radnet.com